Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer
Status:
Not yet recruiting
Trial end date:
2024-02-15
Target enrollment:
Participant gender:
Summary
This phase III trial compares olanzapine to placebo in decreasing nausea and vomiting in
patients with cancer that has spread to other places in the body (advanced). Patients with
advanced cancer may experience nausea and/or vomiting that is unrelated to chemotherapy or
radiation. Giving olanzapine may help reduce nausea and increase appetite in patients who
have advanced cancer.